ArticleFrontiers in immunology2026
Peripheral and central inflammation in progressive supranuclear palsy syndrome: an immunological and imaging neuroinflammation study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neuroinflammation plays an important role in the pathobiology of Progressive Supranuclear Palsy Syndrome (PSP-S). However, it is not adequately known whether peripheral inflammation correlates to neuroinflammation in PSP-S. This study aimed to examine a link between peripheral and brain inflammation in PSP-S by integrating blood and cerebrospinal fluid (CSF) inflammatory profile and Positron Emission Tomography (PET)-Magnetic Resonance Imaging (MRI) (PET-MRI). Methods: Fifty-six PSP-S patients and equal number of healthy controls were recruited. Plasma Th17 pathway cytokine (IL-6, IL-1β, IL-4, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, sCD40L, and TNF-α) levels were measured in all the study participants. CSF levels of these cytokines were measured only in PSP-S patients. The expressions of NF-κB ( Results: Inflammasome ( Conclusion: Both systemic inflammation and neuroinflammation are evident in PSP-S. The positive correlation of higher plasma IL-1β levels with neuroinflammation provides preliminary evidence towards the influence of specific peripheral inflammatory molecule on neuroinflammatory basis of PSP-S. The altered immune elements of the current study further reinforce the pathogenic relevance of immune-inflammatory pathways in PSP-S pathobiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.